dc.contributor.author | Gonzalez-Espinoza, Liliana | |
dc.contributor.author | Ortiz Arduán, Alberto | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) | es_ES |
dc.date.accessioned | 2016-06-08T16:38:51Z | |
dc.date.available | 2016-06-08T16:38:51Z | |
dc.date.issued | 2015-01-01 | |
dc.identifier.citation | Clinical Kidney Journal 8 (2015): 243–247 | es_ES |
dc.identifier.issn | 2048-8505 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/671349 | |
dc.description.abstract | The 2012 ERA-EDTA Registry Annual Report contains both good news and bad news. On the bright
side, the 2-year survival of patients starting renal replacement therapy (RRT) for chronic kidney
disease (CKD), on dialysis or receiving a living-related kidney transplantation, has progressively increased
to 82.2, 79.7 and 98.3%, respectively, whereas for cadaveric kidney transplantation it
remains stable (96.0–96.1%). On the dark side, inequalities persist between European citizens in
access to renal transplantation and in incidence and prevalence of RRT. Living in Greece, Belgium
(French- or Dutch-speaking) or Portugal (the GBP countries) is associated with higher chances of
initiating RRT than living in other European countries. The adjusted RRT incidence for GBP countries
was 188, 201-174 and 220* (* unadjusted) pmp in 2012, respectively (versus 122, 114 and 97 pmp
in the Netherlands or two Spanish regions bordering Portugal). In lower income countries, a low
RRT incidence may represent lack of access to needed healthcare (e.g. Montenegro 26 pmp).
However, how can the high incidence and prevalence of RRT in the GBP countries be explained? Do
GBP citizens have access to RRT that is denied, rejected or considered unnecessary in other high
income countries? Does the GBP healthcare system fail to prevent progression of CKD? Do local
genetic or environmental factors favour CKD progression? Unravelling the underlying reasons is an
urgent research need: only an understanding of the causes will allow correction of the problem.
Unavailability of data from some large countries (e.g. Germany and Italy) is not helpful | en_US |
dc.description.sponsorship | Grant support was provided by ISCIII and
FEDER funds PI13/00047, Sociedad Española de Nefrologia,
ISCIII-RETIC REDinREN/RD012/0021, Comunidad de Madrid CIFRA
S2010/BMD-2378. Salary support was provided by Programa
Intensificación Actividad Investigadora (ISCIII/Agencia Laín-
Entralgo/CM) to A.O. | en_US |
dc.format.extent | 5 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | Oxford University Press | en |
dc.relation.ispartof | Clinical Kidney Journal | en |
dc.rights | © The Author 2015 | en_US |
dc.subject.other | Access to healthcare | en_US |
dc.subject.other | Chronic kidney disease | en_US |
dc.subject.other | Dialysis | en_US |
dc.subject.other | Inequality | en_US |
dc.subject.other | Mortality | en_US |
dc.title | 2012 ERA-EDTA Registry annual report: Cautious optimism on outcomes, concern about persistent inequalities and data black-outs | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.1093/ckj/sfv035 | es_ES |
dc.identifier.doi | 10.1093/ckj/sfv035 | es_ES |
dc.identifier.publicationfirstpage | 243 | es_ES |
dc.identifier.publicationissue | 3 | es_ES |
dc.identifier.publicationlastpage | 247 | es_ES |
dc.identifier.publicationvolume | 8 | es_ES |
dc.relation.projectID | Comunidad de Madrid. S2010/BMD-2378/CIFRA | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en_US |
dc.rights.cc | Reconocimiento – NoComercial | es_ES |
dc.rights.accessRights | openAccess | en |
dc.facultadUAM | Facultad de Medicina | |